Open-label Adjunctive Zonisamide for Bipolar Disorder

• Status: Terminated
• Trial end date: 2002-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elan Pharmaceuticals
• Treatments: Zonisamide

Criteria

• Bipolar I/II

• Average intelligence

• Taking at least one, but no more than two mood stabilizers